Alkeon Capital Management
NVCR icon

Alkeon Capital Management’s NovoCure NVCR Stock Holding History

Alkeon Capital Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-196,609
Closed -$2.85M – 57
2016
Q1 		$2.85M Sell
196,609
-178,391
-48% -$2.56M 0.06% 49
2015
Q4 		$8.38M Buy
+375,000
New +$8.96M 0.17% 49

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Alkeon Capital Management's NVCR Position: Q2 2016 in Review

Alkeon Capital Management sold out of NovoCure (NVCR) in Q2 2016, closing a stake of 196,609 shares — an estimated $2.85M sold.

Alkeon Capital Management first reported a position in NVCR in Q4 2015 and held it in 2 quarters. The position peaked at $8.38M in Q4 2015. 66 funds tracked by Wall St. Rank hold NVCR as of Q2 2016.

  • Alkeon Capital Management reported no remaining NovoCure position as of Q2 2016 after selling out during the quarter.
  • Alkeon Capital Management sold 196,609 NovoCure shares in Q2 2016, an estimated $2.85M.
  • Alkeon Capital Management first reported a position in NovoCure in Q4 2015 and held it in 2 quarters.
  • Alkeon Capital Management's NovoCure position peaked at $8.38M in Q4 2015.
  • 66 funds tracked by Wall St. Rank held NovoCure as of Q2 2016.

Based on Alkeon Capital Management's 13F filing for Q2 2016, filed 15 Aug 2016.